News Daily News FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil Michael O'Riordan December 14, 2022
News Daily News Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use L.A. McKeown October 05, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Conference News TCT 2022 HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza Todd Neale September 16, 2022
News Conference News ESC 2022 PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 Michael O'Riordan August 27, 2022
News Daily News Quadruple Therapy Costs Prohibitive for Many HFrEF Patients L.A. McKeown June 21, 2022
News Conference News ACC 2022 DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF L.A. McKeown April 08, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia L.A. McKeown March 22, 2022
News Daily News Guideline-Directed Therapies Underused in Frail HF Patients L.A. McKeown March 11, 2022
News Daily News FDA Approves Empagliflozin for Treatment of HFpEF Michael O'Riordan February 24, 2022
News Conference News THT 2022 Probe Beyond Ejection Fraction to Understand and Manage HFpEF L.A. McKeown February 07, 2022